MedTrace Logo

Morbidity and Mortality Follow Up for the Scleroderma Lung Study

NCT01762449 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 158

Last updated 2014-01-23

No results posted yet for this study

Summary

The primary intent of this study is to add to the body of knowledge on scleroderma patients with interstitial lung disease. While lung disease is recognized as the leading cause of death amongst patients with scleroderma, there is not a large body of literature describing the long-term morbidity and mortality rate of these scleroderma patients. For this reason, the investigators are following participants of the Scleroderma Lung Study (NCT00004563) after their participation in that study was concluded. In addition, the investigators will assess if the subjects who received one year of oral cyclophosphamide in the Scleroderma Lung Study experienced progression of their scleroderma-related lung disease following the end of the study.

Conditions

  • Scleroderma

Interventions

OTHER

Followup survey

Sponsors & Collaborators

Principal Investigators

  • Keith Sullivan, MD · Duke University

  • Daniel Furst, MD · University of California, Los Angeles

  • Donald Tashkin, MD · University of California, Los Angeles

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-06-30
Completion
2013-08-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01762449 on ClinicalTrials.gov